Protection induced by a glycoprotein E-deleted bovine herpesvirus type 1 marker strain used either as an inactivated or live attenuated vaccine in cattle

Table 1 Experimental design

Experiment	Vaccine	# animals	Vaccination time (dpv) [route, vol.]	Challenge (dpv)	BoHV-1 antibodies (dpv)	BoHV-1 sheeding (dpv/dpc)	LPT (dpv/dpc)
inactivated BoHV-1ΔgEβgal vaccine	BoHV-1ΔgEβgal	5	0, 21 [SC, 3 ml]	186	0, 14, 21, 30, 67, 150 and 186	0, 3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc	7,72 dpv
	BoHV-1LA	5	0, 21 [SC, 3 ml]	186
	mock	6	0, 21 [SC, 3 ml]	186
attenuated BoHV-1ΔgEβgal vaccine	BoHV-1ΔgEβgal	5	Group 1: 0 [IN, 4 ml]	42	0, 7, 19, 34 and 42	1 to 42dpv	7,30 dpc
		5	Group 2: 0 [IM, 4 ml]	42		and
	Sentinel	5	Group 4			3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc
	Mock	5	Group 5	42		3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc
attenuated BoHV-1ΔgEβgal vaccine SAFETY	BoHV-1ΔgEβgal	5	Group 3: 0 [IV, 4 ml]		along 370

SC: subcutaneous, dpv: days post-vaccination; dpc: days post-challenge.
During the next 42 days post- vaccination with attenuated BoHV-1ΔgEβgal, viral excretion was controlled, as well as clinical signs such as loss of appetite, lesions of nasal, ocular and oral mucosae and discharge from the nose or eyes and rectal temperature. General clinical status was evaluated and recorded using a rating system (ranging from 0 = asymptomatic to 3 = severe symptoms). Nasal swabs were scored as follows: 0 = absent, 1 = slightly serous, 2 = severely serous, 3 = seromucous, 4 = mucopurulent.

ISSN: 1746-6148